Myasthenia Gravis is an autoimmune condition where antibodies that inhibit function of the neurotransmitter acetylcholine. This occurs at the neuromuscular junctions neuromuscular disease so it is characterized by symptoms of fluctuating muscle weakness and fatigability. In addition to muscular fatigue difficulty with swallowing or breathing, speech or vision may be seen. In addition to immunosuppressive therapy, MG is treated medically with acetylcholinesterase inhibitors or even surgically with thymectomy. Animal model studies are ongoing as reported in the Scandinavian Journal of Immunology in 2010, a study demonstrated that hMSC (mesenchymal stem cells) treatment was therapeutically useful in autoimmune myasthenia gravis mice, and the underlying mechanism may relate with their immunomodulatory potential (read more). Ongoing human research to evaluate the effects of stem cells on auto-immune conditions is also underway.
Myasthenia Gravis and OC Regenerative Medicine
As part of the CELL SURGICAL NETWORK we offer a specific SVF deployment protocol that attempts to mitigate the effects of Myasthenia Gravis. SVF (rich in mesenchymal stem cells and growth factors) has immuno-regulatory and anti-inflammatory properties which may be beneficial. SVF is deployed systemically as an outpatient at the time of SVF harvesting and procurement. The entire cellular surgical procedure takes approximately three hours.
At OC Regenerative Medicine we truly care about our Myasthenia Gravis patients. We take the time to provide our patients with what they need to achieve their goals. By filling out Confidential Candidate Application, we will answer the questions and concerns you may have about our protocols for Myasthenia Gravis.